Trial literature on lymphomas

Literature on trials concerning Hodgkin Lymphoma und Non-Hodgkin Lymphoma

Last modification: 2024/05/03 https://kinderkrebsinfo.de/doi/e123829

Hodgkin Lymphoma (Hodgkin Disease)

Trial literature on Hodgkin lymphoma

Pubmed

  1. Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R: Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. The Lancet. Oncology 2023, 24: 252 [PMID: 36858722] MAU2023
  2. Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH: Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology 2022, 23: 125 [PMID: 34895479] MAU2022
  3. Kluge R, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D: Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021, 62: 338 [PMID: 32764122] KLU2021
  4. Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Körholz D, Stoevesandt D: Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial. Pediatric blood & cancer 2021, 68:e28903 [PMID: 33538093] KUR2021
  5. Daw S, Hasenclever D, Mascarin M, Fernández-Teijeiro A, Balwierz W, Beishuizen A, Burnelli R, Cepelova M, Claviez A, Dieckmann K, Landman-Parker J, Kluge R, Körholz D, Mauz-Körholz C, Wallace WH, Leblanc T: Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere 2020, 4:e329 [PMID: 32072145] DAW2020
  6. Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A: Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia 2020, 34: 151 [PMID: 31431735] DES2020
  7. Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D, Sabri O, Mauz-Körholz C: 18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required? Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018, 59: 1524 [PMID: 29653979] GEO2018
  8. Kampers J, Orjuela-Grimm M, Schober T, Schulz TF, Stiefel M, Klein C, Körholz D, Mauz-Körholz C, Kreipe H, Beier R, Maecker-Kolhoff B: Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leukemia & lymphoma 2017, 58: 633 [PMID: 27685149] KAM2017
  9. Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F, Kurch L, Georgi T, Dietlein M, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Wilson L, Bergstraesser E, Sabri O, Mauz-Körholz C, Körholz D, Hasenclever D: Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma. PloS one 2016, 11:e0149072 [PMID: 26963909] KLU2016
  10. Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, Kluge R, Körholz D: Pediatric Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Sep 20; 33: 2975 [PMID: 26304892] MAU2015a
  11. Mauz-Körholz C, Lange T, Hasenclever D, Burkhardt B, Feller AC, Dörffel W, Kluge R, Vordermark D, Körholz D: Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klinische Padiatrie 2015, 227(6-7): 314 [PMID: 26356319] MAU2015
  12. Mauz-Körholz C, Hasenclever D, Holzendorf V, Bernstädt M, Jürgens H, Burdach S, Eggert A, Berthold F, Müller HL, Frühwald MC, Klingebiel T, Metzler M, Körholz D: Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. Leukemia & lymphoma 2014, 1 [PMID: 25204374] MAU2014
  13. Körholz D, Mauz-Körholz C, Vordermark D, Kluge R, Dieckmann K: Increased relapse rates in early stage hodgkin lymphoma (HL) patients without radiotherapy: the German Society of Radiooncology (DEGRO) advises to treat all early stage HL patients with radiotherapy. Klinische Padiatrie 2014, 226(6-7): 307 [PMID: 25431863] KOE2014
  14. Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, Landman-Parker J, Moryl-Bujakowska A, Cepelová M, Karlén J, Álvarez Fernández-Teijeiro A, Attarbaschi A, Fosså A, Pears J, Hraskova A, Bergsträsser E, Beishuizen A, Uyttebroeck A, Schomerus E, Sabri O, Körholz D, Kluge R: qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. European journal of nuclear medicine and molecular imaging 2014, 41: 1301 [PMID: 24604592] HAS2014
  15. Schellong G, Riepenhausen M, Ehlert K, Brämswig J, Dörffel W, Schmutzler R, Rhiem K, Bick U: Brustkrebs bei jungen Frauen nach Therapie eines Hodgkin-Lymphoms im Kindes- und Jugendalter: Eine Beobachtungsstudie mit bis zu 33 Jahren Follow-up. Dtsch Arztebl Int 2014, 111(1-2): 3 [URI: http://www.aerzteblatt.de/ archiv/ 152680/ Brustkrebs-bei-jungen-Frauen-nach-Therapie-eines-Hodgkin-Lymphoms-im-Kindes-und-Jugendalter-Eine-Beobachtungsstudie-mit-bis-zu-33-Jahren-Follow-up?src=search] SCH2014
  16. Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G: Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31: 1562 [PMID: 23509321] DOE2013
  17. Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, Borkhardt A, Seeger K, Lehrnbecher T, Kulozik A, Rößler J, Burdach S, Jürgens H, Körholz D: Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL). Klinische Padiatrie 2012t; 224: 377 [PMID: 23047832] HAA2012
  18. Kluge R, Körholz D: [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klinische Padiatrie 2011, [Epub ahead of print] [PMID: 22012607] KLU2011a
  19. Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdörfer P, Ehlert K, Becker M, Rössler J, Kulozik AE, Sabri O, Kluge R: [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 10; 29: 3523 [PMID: 21825262] PUR2011
  20. Pinkwart C, Stiefel M, Mauz-Körholz C, Körholz D: [Akute Psychose bei einer jugendlichen Patientin während der Therapie eines nodulären lymphozytenprädominanten Hodgkin-Lymphoms (nLPHL) Stadium IIB]. Klinische Padiatrie 2011, 223: 370 [PMID: 22052634] PIN2011
  21. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, Dieckmann K, Pötter R, Heinecke A, Brämswig J, Dörffel W: Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatric blood & cancer 2010, 55: 1145 [PMID: 20734400] SCH2010j
  22. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. Journal of clinical oncology 2010, [PMID: 20625128] MAU2010
  23. Staege MS, Körholz D: New treatment strategies for Hodgkin's lymphoma. Leukemia research 2009, 33: 886 [PMID: 19233468] STA2009b
  24. Foell JL, Max D, Giersberg C, Körholz D, Staege MS: Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine. Anticancer research 2008, 28: 887 [PMID: 18507033] FOE2008
  25. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, Richter G, Mauz-Körholz C, Föll J, Körholz D: Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Experimental hematology 2008, 36: 886 [PMID: 18400362] STA2008
  26. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dörffel W, Wallace WH, Schellong G, Robert A, Körholz D, Oberlin O, Hall GW, Landman-Parker J: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007, 110: 179 [PMID: 17526010] MAU2007
  27. Banning U, Barthel H, Mauz-Körholz C, Kluge R, Körholz D, Sabri O: Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells. European journal of haematology 2006, 77: 102 [PMID: 16800842] BAN2006
  28. Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, Bokkerink JP, Riepenhausen M, Luders H, Potter R, Ruhl U, DAL/GPOH: Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. Journal of clinical oncology 2005, 23: 6181 [PMID: 16135485] SCH2005l
  29. Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, Dörffel W, Wickmann L, Papsdorf K, Dieckmann K, Kahn T, Mauz-Korholz C, Dannenberg C, Potter R, Brosteanu O, Schellong G, Sabri O: The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease. Klin Pädiatr 2004, 216: 150 [PMID: 15175959] KOE2004
  30. Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O: Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie 2003, 26: 489 [PMID: 14605468] KOE2003

Non-Hodgkin Lymphoma (NHL)

Literature on Non-Hodgkin Lymphoma

Pubmed

  1. Knörr F, Woessmann W: Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response. British journal of haematology 2023, 200: 107 [PMID: 36259567] KNO2023
  2. Beishuizen A, Mellgren K, Andrés M, Auperin A, Bacon CM, Bomken S, Burke GAA, Burkhardt B, Brugieres L, Chiang AKS, Damm-Welk C, d'Amore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley MC, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu-Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner SD, European Intergroup for Childhood Non-Hodgkin Lymphoma: Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. The Lancet. Haematology 2023, 10:e213-e224 [PMID: 36858678] BEI2023
  3. Rigaud C, Knörr F, Brugières L, Woessmann W: Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best practice & research. Clinical haematology 2023, 36: 101444 [PMID: 36907641] RIG2023
  4. Temple WC, Mueller S, Hermiston ML, Burkhardt B: Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best practice & research. Clinical haematology 2023, 36: 101449 [PMID: 36907639] TEM2023
  5. Au-Yeung RKH, Padilla LA, Zimmermann M, Reinke S, Oschlies I, Escherich G, Woessmann W, Burkhardt B, Klapper W: Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma. Leukemia 2023, 37: 488 [PMID: 36352192] AUY2023
  6. Richter J, John K, Staiger AM, Rosenwald A, Kurz K, Michgehl U, Ott G, Franzenburg S, Kohler C, Finger J, Oschlies I, Paul U, Siebert R, Spang R, Burkhardt B, Klapper W: Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British journal of haematology 2022, 196: 681 [PMID: 34617271] RIC2022
  7. Richter J, John K, Staiger AM, Rosenwald A, Kurz K, Michgehl U, Ott G, Franzenburg S, Kohler C, Finger J, Oschlies I, Paul U, Siebert R, Spang R, Burkhardt B, Klapper W: Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. British journal of haematology 2022, 196: 681 [PMID: 34617271] RIC2022
  8. Bethke M, Varga G, Weinhage T, Sabharwal H, Mellgren K, Randau G, Rolfing M, Wittkowski H, Foell D, Michgehl U, Burkhardt B: Patient parameters and response after administration of rituximab in pediatric mature B-cell non-Hodgkin lymphoma. Pediatric blood & cancer 2022, 69:e29514 [PMID: 34939314] BET2022
  9. Ruether C, Wuensch C, Randau G, Michgehl U, Trautmann M, Hartmann W, Sandmann S, Dugas M, Khanam T, Burkhardt B: Design of a targeted next-generation DNA sequencing panel for pediatric T-cell lymphoblastic lymphoma to unravel biology and optimize treatment. Genes, chromosomes & cancer 2022, 61: 459 [PMID: 35278000] RUE2022
  10. Damm-Welk C, Lovisa F, Contarini G, Lüdersen J, Carraro E, Knörr F, Förster J, Zimmermann M, Sala A, Vinti L, Tondo A, Pillon M, Woessmann W, Mussolin L: Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials? Cancers 2022, 14 [PMID: 35406475] DAM2022
  11. Möker P, Zur Stadt U, Zimmermann M, Alawi M, Mueller S, Finger J, Knörr F, Riquelme A, Oschlies I, Klapper W, Bradtke J, Burkhardt B, Woessmann W, Damm-Welk C: Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia. Leukemia 2022, 36: 2343 [PMID: 35790817] MOE2022
  12. Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G: Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nature communications 2022, 13: 3881 [PMID: 35794096] BUR2022
  13. Knörr F, Woessmann W: Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response. British journal of haematology 2023, 200: 107 [PMID: 36259567] KRO2022
  14. Au-Yeung RKH, Richter J, Iaccarino I, Abramov D, Bacon CM, Balagué O, d'Amore ESG, Simonitsch-Klupp I, Hebeda K, Nakazawa A, Oschlies I, Kontny U, Woessmann W, Burkhardt B, Klapper W: Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. Pediatric blood & cancer 2021, 68:e29285 [PMID: 34390161] AUY2021
  15. Au-Yeung RKH, Richter J, Iaccarino I, Abramov D, Bacon CM, Balagué O, d'Amore ESG, Simonitsch-Klupp I, Hebeda K, Nakazawa A, Oschlies I, Kontny U, Woessmann W, Burkhardt B, Klapper W: Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. Pediatric blood & cancer 2021, 68:e29285 [PMID: 34390161] AUY2021
  16. Nägele V, Zugmaier G, Goebeler ME, Viardot A, Bargou R, Kufer P, Klinger M: Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab. Experimental hematology 2021,S0301-472X00245 [PMID: 34228983] NAE2021
  17. Burkhardt B, Taj M, Garnier N, Minard-Colin V, Hazar V, Mellgren K, Osumi T, Fedorova A, Myakova N, Verdu-Amoros J, Andres M, Kabickova E, Attarbaschi A, Chiang AKS, Bubanska E, Donska S, Hjalgrim LL, Wachowiak J, Pieczonka A, Uyttebroeck A, Lazic J, Loeffen J, Buechner J, Niggli F, Csoka M, Krivan G, Palma J, Burke GAA, Beishuizen A, Koeppen K, Mueller S, Herbrueggen H, Woessmann W, Zimmermann M, Balduzzi A, Pillon M: Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers 2021, 13 [PMID: 33923026] BUR2021
  18. Khanam T, Sandmann S, Seggewiss J, Ruether C, Zimmermann M, Norvil AB, Bartenhagen C, Randau G, Mueller S, Herbrueggen H, Hoffmann P, Herms S, Wei L, Woeste M, Wuensch C, Gowher H, Oschlies I, Klapper W, Woessmann W, Dugas M, Burkhardt B: Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood 2021, 137: 2347 [PMID: 33152759] KHA2021
  19. Moser O, Zimmermann M, Meyer U, Klapper W, Oschlies I, Schrappe M, Attarbaschi A, Mann G, Niggli F, Spix C, Kontny U, Klingebiel T, Reiter A, Burkhardt B, Woessmann W: Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica 2021, 106: 1390 [PMID: 32299903] MOS2021
  20. Ronceray L, Abla O, Barzilai-Birenboim S, Bomken S, Chiang AK, Jazbec J, Kabickova E, Lazic J, Beishuizen A, Mellgren K, Tanaka F, Pillon M, Devalck C, Gouttenoire M, Makarova O, Burkhardt B, Attarbaschi A, European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group: Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatric blood & cancer 2018, 65 [PMID: 29286565] RON2018
  21. Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W: Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 2018, 103: 477 [PMID: 29242300] KNO2018
  22. Ruf S, Hebart H, Hjalgrim LL, Kabickova E, Lang P, Steinbach D, Schwabe GC, Woessmann W: CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatric blood & cancer 2018, 65:e27003 [PMID: 29512859] RUF2018
  23. Langer T, Grabow D, Steinmann D, Wörmann B, Calaminus G: Late Effects and Long-Term Follow-Up after Cancer in Childhood. Oncology research and treatment 2017, 40: 746 [PMID: 29183026] LAN2017
  24. Paul U, Richter J, Stuhlmann-Laiesz C, Kreuz M, Nagel I, Horn H, Staiger AM, Aukema SM, Hummel M, Ott G, Spang R, Rosenwald A, Feller AC, Cogliatti S, Stein H, Hansmann ML, Moller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Truemper L, Siebert R, Klapper W: Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leukemia & lymphoma 2018, 59: 1213 [PMID: 28838257] PAU2017
  25. Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y: Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017, 102: 2086 [PMID: 28983060] LAN2017
  26. Burkhardt B, Mueller S, Khanam T, Perkins SL: Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. British journal of haematology 2016, 173: 545 [PMID: 26991119] BUR2016a
  27. Rohde M, Bonn BR, Zimmermann M, Lange J, Möricke A, Klapper W, Oschlies I, Szczepanowski M, Nagel I, Schrappe M, MMML-MYC-SYS Project, ICGC MMML-Seq Project, Loeffler M, Siebert R, Reiter A, Burkhardt B: Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Muenster protocols. Haematologica 2017, 102: 1091 [PMID: 28209658] ROH2016
  28. Lange J, Lenz G, Burkhardt B: Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. Expert review of hematology 2017, 10: 123 [PMID: 27936978] LAN2016
  29. Burkhardt B, Yavuz D, Zimmermann M, Schieferstein J, Kabickova E, Attarbaschi A, Lisfeld J, Reiter A, Makarova O, Worch J, Bonn BR, Damm-Welk C: Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Annals of hematology 2016, 95: 1503 [PMID: 27376362] BUR2016
  30. K Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W: Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma. Clinical and experimental immunology 2016, 186: 96 [PMID: 27414060] SIN2016
  31. Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M, European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group: Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica 2016, 101: 1581 [PMID: 27515251] ATT2016
  32. Hebart H, Lang P, Woessmann W: Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report. Annals of internal medicine 2016, 165: 607 [PMID: 27750310] HEB2016
  33. Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS: Revised International Pediatric Non-Hodgkin Lymphoma Staging System. Journal of clinical oncology 2015, 33: 2112 [PMID: 25940716] ROS2015
  34. Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, Janda A, Attarbaschi A, Niggli F, Zimmermann M, Reiter A, Klapper W: Non-anaplastic peripheral T-cell lymphoma in children and adolescents - a retrospective analysis of the NHL-BFM study group. British journal of haematology 2015, 168: 835 [PMID: 25395120] KON2015
  35. Bartram T, Burkhardt B, Wössmann W, Seidemann K, Zimmermann M, Cario G, Lisfeld J, Ellinghaus E, Franke A, Houlston RS, Schrappe M, Reiter A, Stanulla M: Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group. Leukemia & lymphoma 2014,: 1 [PMID: 25005032] BAR2014
  36. Thorer H, Zimmermann M, Makarova O, Oschlies I, Klapper W, Lang P, von Stackelberg A, Fleischhack G, Worch J, Jürgens H, Woessmann W, Reiter A, Burkhardt B: Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Münster protocols for systemic lymphoma. Haematologica 2014, [PMID: 25107886] THO2014
  37. Bonn BR, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, Wrobel G, Attarbaschi A, Escherich G, Klapper W, Reiter A, Burkhardt B: Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013, 18; 121: 3153 [PMID: 23396305] BON2013
  38. Reiter A: Non-Hodgkin Lymphoma in Children and Adolescents. Klinische Padiatrie 2013, 225(S 01):S87-S93 [PMID: 23700066] REI2013
  39. Lueth M, Stein H, Spors B, Henze G, Driever PH: First case report of a peripheral T-cell lymphoma, not otherwise specified, of the central nervous system in a child. Journal of pediatric hematology/oncology 2012, 34:e66 [PMID: 22367391] LUE2012
  40. Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, Lang P, Attarbaschi A, Mann G, Oschlies I, Klapper W, Reiter A: Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study. J Clin Oncol 2011, [Epub ahead of print] [PMID: 21709186] WOE2011
  41. Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugières L, Le Deley MC, on behalf of European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL): Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. Pediatr Blood Cancer 2011, Epub ahead of print [DOI: 10.1002/pbc.22940] WRO2011
  42. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of clinical oncology 2010, 28: 3115 [PMID: 20516455] MEI2010a
  43. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010 1; 28: 3987 [PMID: 20679620] DEL2010
  44. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W: Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010, 115: 3314 [PMID: 20185586] AIT2010
  45. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British journal of haematology 2010, 149: 578 [PMID: 20331465] CAI2010
  46. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. Journal of clinical oncology 2009, 27: 3363 [PMID: 19433688] BUR2009
  47. Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A: Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group. Journal of clinical oncology 2009, 27: 897 [PMID: 19139435] BRU2009
  48. Landmann E, Oschlies I, Zimmermann M, Moser O, Graf N, Suttorp M, Greiner J, Reiter A, Berlin-Frankfurt-Münster group: Secondary non-Hodgkin lymphoma (NHL) in children and adolescents after childhood cancer other than NHL. British journal of haematology 2008, 143: 387 [PMID: 18729852] LAN2008a
  49. Reiter A, Klapper W: Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. British journal of haematology 2008, 142: 329 [PMID: 18537979] REI2008
  50. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24: 491 [PMID: 16421426] BUR2006
  51. Stanulla M, Seidemann K, Schnakenberg E, Book M, Mehles A, Welte K, Schrappe M, Reiter A: Methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and risk of pediatric non-Hodgkin lymphoma in a German study population. Blood 2005, 105: 906 [PMID: 15632215] STA2005b
  52. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131: 39 [PMID: 16173961] BUR2005a
  53. Borkhardt A, Wuchter C, Viehmann S, Pils S, Teigler-Schlegel A, Stanulla M, Zimmermann M, Ludwig W, Janka-Schaub G, Schrappe M, Harbott J: Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002, 16: 1685 [PMID: 12200682] BOR2002
  54. Reiter A, Schrappe M, Ludwig W, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma. Blood 2000, 95: 416 [PMID: 10627444] REI2000c
  55. Reiter A, Schrappe M, Tiemann M, Ludwig W, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Pluss H, Zintl F, Henze G, Riehm H: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy. Blood 1999, 94: 3294 [PMID: 10552938] REI1999b
  56. Reiter A, Seidemann K, Schrappe M: Therapie der Non-Hodgkin-Lymphome im Kindesalter. Klin Onkologie 1997, 16 REI1997b
  57. Reiter A, Riehm H: Large-cell lymphomas in children. The Non-Hodgkin-Lymphomas 1997, 829 REI1997a
  58. Reiter A: Non-Hodgkin-Lymphome. Diagnostische und therapeutische Standards 1997, 89 REI1997